Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4A | O75164 | 1/20 | 0.41 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.41 |
| ▸ | PRMT5 | O14744 | 5/20 | 0.40 |
| ▸ | WDR77 | Q9BQA1 | 5/20 | 0.40 |
| ▸ | NAAA | Q02083 | 1/20 | 0.40 |
| ▸ | HTR2A | P28223 | 1/20 | 0.40 |
| ▸ | IKBKB | O14920 | 3/20 | 0.39 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.38 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.38 |
| ▸ | NAMPT | P43490 | 1/20 | 0.38 |
| ▸ | CHUK | O15111 | 1/20 | 0.37 |
| ▸ | CSF1R | P07333 | 1/20 | 0.37 |
| ▸ | BTK | Q06187 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12578590 | 0.84 | KCNA5 (0.47) | KDM4AKCNA5NAMPT | |
| SCHEMBL1668565 | 0.81 | JAK3 (0.48) | NAMPT | |
| SCHEMBL14907991 | 0.78 | HPGDS (0.47) | KCNA5PRMT5WDR77NAMPT | |
| SCHEMBL12284513 | 0.76 | HTR2A (0.47) | NAAAHTR2AIKBKBSLC6A2SLC6A4 | |
| SCHEMBL27747024 | 0.76 | HTR2A (0.47) | NAAAHTR2AIKBKBSLC6A2SLC6A4 | |
| SCHEMBL17303812 | 0.75 | HTR2A (0.56) | HTR2ASLC6A2SLC6A4SLC6A3 | |
| SCHEMBL19170763 | 0.75 | HTR2A (0.56) | HTR2ASLC6A2SLC6A4SLC6A3 | |
| SCHEMBL16417582 | 0.75 | HTR2A (0.56) | HTR2ASLC6A2SLC6A4SLC6A3 | |
| SCHEMBL30159605 | 0.75 | KCNA5 (0.56) | KDM4AKCNA5NAMPT | |
| SCHEMBL8018113 | 0.75 | KCNA5 (0.56) | KDM4AKCNA5NAMPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9771345-B2 | Coferons and methods of making and using them | CORNELL UNIVERSITY (US) | 2017-09-26 | — | — | US | disclosed |
| US-20120295874-A1 | COFERONS AND METHODS OF MAKING AND USING THEM | CORNELL UNIVERSITY (US) | 2012-11-22 | — | — | US | disclosed |
| EP-2485678-A1 | COFERONS AND METHODS OF MAKING AND USING THEM | Cornell University (US) | 2012-08-15 | — | — | EP | disclosed |
| WO-2011043817-A1 | COFERONS AND METHODS OF MAKING AND USING THEM | CORNELL UNIVERSITY (US) | 2011-04-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120295874-A1 | COFERONS AND METHODS OF MAKING AND USING THEM | MYOF, FTH1, HCCS | KDM4A 4151/4885KCNA5 4598/4885PRMT5 3114/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.